VYGR Voyager Therapeutics Inc.

13.37
-0.42  -3%
Previous Close 13.79
Open 13.77
Price To Book 4.58
Market Cap 495,670,649
Shares 37,073,347
Volume 376,192
Short Ratio
Av. Daily Volume 400,320
Stock charts supplied by TradingView

NewsSee all news

  1. Voyager Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Highlights

    CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today

  2. Voyager Therapeutics to Host Third Quarter 2019 Financial Results and Corporate Highlights Conference Call

    CAMBRIDGE, Mass., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today

  3. Voyager Therapeutics to Present at Upcoming Investor Conferences in October 2019

    CAMBRIDGE, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases,

  4. Voyager Therapeutics to Present at Upcoming Investor Conferences in September 2019

    CAMBRIDGE, Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial ongoing. Phase 1b longer term data due 2020.
VY-AADC01
Advanced Parkinson’s disease

Latest News

  1. Voyager Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Highlights

    CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today

  2. Voyager Therapeutics to Host Third Quarter 2019 Financial Results and Corporate Highlights Conference Call

    CAMBRIDGE, Mass., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today

  3. Voyager Therapeutics to Present at Upcoming Investor Conferences in October 2019

    CAMBRIDGE, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases,

  4. Voyager Therapeutics to Present at Upcoming Investor Conferences in September 2019

    CAMBRIDGE, Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today